CliffBio
small molecule

DECITABINE

DECITABINE

Loss of exclusivity—loss of exclusivity
CompanyCipla →See this company's full patent-cliff portfolio

Drug detail

Brand nameDECITABINE
Active ingredientDECITABINE
Strength50MG/VIAL
Dosage formINJECTABLE
RouteINTRAVENOUS
ModalitySmall molecule
FDA approvalNovember 2017
Marketing statusDISCN

More from Cipla

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

DECITABINE patent cliff — loss of exclusivity — | CliffBio